Weekly Bio-Techne Corporation (NASDAQ:TECH) Ratings as of Apr 16, 2018

April 16, 2018 - By Darrel Chase

Bio-Techne Corporation (NASDAQ:TECH) Corporate Logo
Big Money Sentiment decreased to 0.98 in 2017 Q4. It has change of 0.23, from 2017Q3’s 1.21. The ratio dropped due to Bio-Techne Corporation positioning: 27 sold and 88 reduced. 34 funds amassed holdings and 79 increased holdings. Investors holded 35.91 million in 2017Q3 but now own 35.53 million shares or 1.06% less.
Ubs Asset Americas reported 30,807 shs. Advisory Ser Networks Ltd Limited Liability Company reported 1,112 shs. Gofen And Glossberg Ltd Liability Corp Il stated it has 0.01% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Millennium Mgmt Limited invested 0.01% in Bio-Techne Corporation (NASDAQ:TECH). Financial Bank invested in 11,150 shs or 0.02% of the stock. State Of Tennessee Treasury Department has 70,000 shs for 0.04% of their capital. Stephens Inv Grp Inc Limited Company holds 100,123 shs. Oregon Employees Retirement Fund holds 0.03% of its capital in Bio-Techne Corporation (NASDAQ:TECH) for 13,763 shs. White Pine Cap Ltd Liability Company holds 0.33% in Bio-Techne Corporation (NASDAQ:TECH) or 7,040 shs. Panagora Asset has 0% invested in Bio-Techne Corporation (NASDAQ:TECH) for 2,868 shs. Cap Management has invested 0.09% in Bio-Techne Corporation (NASDAQ:TECH). Thrivent For Lutherans invested 0% in Bio-Techne Corporation (NASDAQ:TECH). 77,603 are held by Intll Gru. Delta Asset Mgmt Ltd Liability Corp Tn reported 8 shs stake. First Mercantile Trust invested in 0.11% or 4,205 shs.

Bio-Techne Corporation had 1 insider sale and 0 insider buys since February 13, 2018. This’s net activity of $680,303.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

Total analysts of 6 have positions in Bio-Techne Corporation (NASDAQ:TECH) as follows: 5 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 83%. Since October 24, 2017 according to StockzIntelligence Inc Bio-Techne Corporation has 9 analyst reports. On Thursday, March 1 the firm has “Buy” rating given by Deutsche Bank. On Wednesday, February 7 Craig Hallum maintained Bio-Techne Corporation (NASDAQ:TECH) rating. Craig Hallum has “Buy” rating and $160.0 target. On Thursday, January 18 Robert W. Baird maintained Bio-Techne Corporation (NASDAQ:TECH) rating. Robert W. Baird has “Buy” rating and $154.0 target. On Tuesday, February 6 the firm has “Buy” rating by Robert W. Baird given. On Wednesday, February 7 Stephens maintained Bio-Techne Corporation (NASDAQ:TECH) with “Hold” rating. The company rating was maintained by Leerink Swann on Tuesday, December 5. On Tuesday, October 31 Robert W. Baird maintained the shares of TECH in report with “Buy” rating. On Monday, October 23 the stock of Bio-Techne Corporation (NASDAQ:TECH) earned “Buy” rating by Robert W. Baird. Listed here are Bio-Techne Corporation (NASDAQ:TECH) PTs and latest ratings.

01/03/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $154 New Target: $163 Maintain
07/02/2018 Broker: Stephens Rating: Hold New Target: $142.0 Maintain
07/02/2018 Broker: Craig Hallum Rating: Buy New Target: $160.0 Maintain
06/02/2018 Broker: Robert W. Baird Rating: Buy New Target: $157.0 Maintain
18/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $154.0 Maintain
05/12/2017 Broker: Leerink Swann Rating: Buy Maintain
31/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $140.0 Maintain
23/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $126.0 Maintain
24/10/2017 Broker: Citigroup Rating: Buy New Target: $145.0

Its shares touched $149.93 on during the last trading session after 0.66% change.Bio-Techne Corporation has volume of 169,085 shares. Since April 16, 2017 TECH has risen 45.31% and is uptrending. TECH outperformed the S&P500 by 33.76%.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The company has $5.62 billion market cap. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.49.3 is the P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

Bio-Techne Corporation (NASDAQ:TECH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.